China Pharmaceutical University has synthesized kaurane tetracyclic diterpenoid derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of arthritis and skin disorders.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of juvenile idiopathic arthritis, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
The stress-responsive protein PPP1R15A (protein phosphatase 1, regulatory subunit 15 A) promotes the unfolded protein response and restores protein homeostasis.
Synthesis and optimization of several series of G-protein coupled receptor 183 (GPR183) antagonists at Immunophage Biomedical Co. Ltd. led to the discovery of a lead candidate with promising potency (IC50=31.3 nM), reduced hERG inhibition and improved aqueous solubility.
Proabtech Co. Ltd. investigators have published findings from the preclinical characterization of PAT-101, a novel recombinant human albumin (rHA)-conjugated urate oxidase (Uox) variant, being developed for the treatment of gout.
N-acetyltransferase 10 (NAT10) is an RNA cytidine acetyltransferase involved in multiple biological processes, such as inflammatory responses or osteogenic differentiation, and linked to pathological states such as asthma, viral infections, cancer, or laminopathies.
Chengdu Baiyu Pharmaceutical Co. Ltd. has disclosed pyrrolidine derivatives acting as IL-6 inhibitors and Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of autoimmune disease.
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. has received FDA clearance of its IND application for a phase I trial in the U.S. of ABP-745, an anti-inflammatory oral small-molecule drug, for the treatment of acute gout.
Aurinia Pharmaceuticals Inc. has submitted an IND application to the FDA for AUR-200, a potential next-generation therapy for B-cell-mediated autoimmune diseases.
RSS
